

Pharma Equity Group

Successful Execution Hinges on Financing



With a new strategy announced in H1-25, Pharma Equity Group (“PEG” or “the Company”) is transitioning toward a diversified investment platform within life sciences , anchored by two Phase II assets with near-term commercialization potential: RNX-011 (peritonitis) and RNX-051 (colorectal cancer). Both are expected to enter pivotal trials in H2-25, with partnering discussions aimed at de-risking execution and securing co-funding. The strategy leverages a capital-light model of drug repositioning and out-licensing, enabling PEG to scale efficiently while maintaining a lean cost base. Supported by a strengthened leadership team and sharpened strategic focus, the Company is well-positioned to unlock meaningful shareholder value, contingent on securing adequate funding to capitalize on upcoming clinical and commercial catalysts. Reflecting the clear prioritization of RNX-011 and RNX-051, we have revised our estimates, resulting in a potential present value of DKK 0.6 (0.8) per share in our Base scenario, derived by a rNPV-model.

▪ **Strategic Shift Aimed at Diversifying the Portfolio**

During Q2-25, PEG launched a revised investment strategy, repositioning the Company as a diversified life science investment platform and expanding beyond pharmaceuticals into Medical Devices and MedTech-segments with shorter development timelines, lower capital intensity, and streamlined regulatory pathways. This marks a clear break from the historic pharma-centric model, aiming to diversify risk and capture value across multiple innovation cycles. However, Reponex remains a core portfolio company under this new framework. The strategy is reinforced by the appointment of Christian Tange as CEO, who brings more than 25 years of experience in financial transformation and transactions. We emphasize that a successful capital raise will be a critical prerequisite for realizing the long-term value potential embedded in this revised investment platform.


▪ **Clinical Progress and Partnering Efforts**

PEG has streamlined the focus to RNX-011 and RNX-051, the two programs with the clearest paths to commercialization. RNX-011 is expected to enter Phase II during Q3-25, with management simultaneously seeking a co-development partner for Phase IIb, which would materially reduce costs and pave the way for a licensing deal. RNX-051 is also advancing toward a Phase IIb trial, where a strategic partnership could de-risk execution and unlock significant licensing potential.

▪ **Streamlined Focus Reflected in Our Forecasts**

We have adjusted our forecasts to reflect PEG’s prioritization of RNX-011 and RNX-051, the candidates with the clearest near-term commercial potential. Consequently, revenue from RNX-041 and RNX-021-23 is deferred to 2027 and 2028, respectively. While this reduces the breadth of near-term pipeline activity, it improves execution visibility and increases the likelihood of reaching value-inflection points despite current funding constraints. The current share price contrasts sharply with our Base case valuation, underscoring the binary nature of the case where licensing agreements will be the decisive catalysts for unlocking shareholder value.


VALUATION RANGE



KEY INFORMATION

Share Price (2025-08-20)	0.14
Shares Outstanding	1,227,556,659
Market Cap (DKKm)	165.7
Net cash(-)/debt(+) (DKKm)	17.6
Enterprise Value (DKKm)	183.4
List	Nasdaq Small Cap Copenhagen
Year-End Report 2025	N/A

SHARE PRICE DEVELOPMENT



TOP SHAREHOLDERS (2025-06-30)

INSIDER

Finansmanagement ApS	16.2%
DMZ Holding ApS	13.1%
Niels Erik Jespersen Holding ApS	5.1%

Estimates (DKKm)	2025E	2026E	2027E	2028E
Risk-adj. Royalties	4.9	10.2	39.2	97.4
COGS	-0.5	-1.0	-2.0	-2.0
Gross profit	4.4	9.2	37.2	95.4
R&D	-6.5	-7.5	-9.0	-10.0
Administrative costs	-12.5	-13.5	-15.0	-15.0
EBIT	-14.6	-11.8	13.2	70.4
Net Income	-15.6	-12.8	9.6	54.1
P/S	34.7	16.6	4.3	1.7
EV/S	38.3	18.3	4.8	1.9
P/E	-10.8	-13.3	17.7	3.1
EV/EBIT	-12.8	-15.9	14.1	2.7

Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, Pharma Equity Group A/S (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2025). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.